Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 1, 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and share allocations rather than corporate financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details the allocation of notional Ordinary Shares and American Depositary Shares (ADSs) to Non-Executive Directors for the service period of April 1, 2016, to June 30, 2016.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that Jesse Goodman was appointed to the Board effective January 1, 2016, and that 25% of his fees will be retained for future reinvestment in the Company's ADSs. The allocations were advised to the Company and Directors on July 1, 2016.
Important Facts for Investors to Verify
- Allocation prices: Notional Ordinary Shares were allocated at £15.59 per share, and notional ADSs at $42.37 per ADS.
- Specific allocations: Sir Philip Hampton received 2,806.286 Ordinary Shares; Professor Sir Roy Anderson received 581.302 ADSs; Vindi Banga received 2,140.172 Ordinary Shares; Stacey Cartwright received 461.033 ADSs; Lynn Elsenhans received 845.582 ADSs; Judy Lewent received 436.213 ADSs; and Urs Rohner received 541.212 Ordinary Shares.
- Board appointment: Jesse Goodman joined the Board on January 1, 2016, with a specific fee retention arrangement for future ADS purchase.